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-Adrenoceptors  are  broadly  distributed  in  various  tissues  of  the  body.  Stress  hormones  regulate  a  panel
of important  physiological  functions  and  disease  states  including  cancer.  Nicotine  and  its  derivatives
could  stimulate  the  release  of  stress  hormones  from  cancer  cells,  leading  to  the  promotion  of cancer
development.  -Blockers  have  been  widely  used  to control  hypertension  for decades.  Recently,  these
agents  could  have  signiﬁcant  implications  in  cancer  therapy  through  blockade  of  adrenoceptors  in tumourtress hormones
umour progression
icotine
-Adrenoceptors
-Adrenergic system
tissues.  In  this  review,  we summarize  recent  advancements  about  the  inﬂuence  of  stress  hormones,
nicotine  and  -adrenoceptors  on  cancer  cell  proliferation,  apoptosis,  invasion  and  metastasis,  and  also
tumour  vasculature  normalization.  Relevant  signal  pathways  and potential  value  of  -blockers  in the
treatment  of  cancer  are also  discussed  in  this  review.-Blockers
ngiogenesis
. Introduction
Hanahan and Weinberg revisited and updated the hallmarks of
ancer in 2011 based on the conceptual progress of cancer in the
ast decade [1]. Two emerging hallmarks combined with previous
ix biological capabilities are widely accepted and acknowledged.
hey constitute the current eight hallmarks of cancer develop-
ent and progression. These include: (1) stimulation of continuous
roliferative signalling, (2) evasion of growth suppressors, (3)
esistance to cell death, (4) potential of limitless replication,
Abbreviations: FAK, focal adhesion kinase; PKA, protein kinase A; BAD,
CL2-associated death protein; VEGF, vascular endothelial growth factor; PlGF,
lacenta-derived growth factor; PDGF, platelet-derived growth factor; TGF-, trans-
orming growth factor ; HIF-1˛, hypoxia-inducible factor-1; IL-6, interleukin-6;
MP, matrix metalloproteinase; TAM, tumor associated macrophages; GRO,
rowth-regulated oncogene alpha; nAChR, nicotinic acetylcholine receptors; NNK,
-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; GABA, -aminobutyric acid;
VC, perivascular cell; EC, endothelial cells; HRG, histidine-rich glycoprotein; DR,
opamine receptor; AC, adenylyl cyclase; cAMP, cyclic AMP; EPAC, exchange pro-
ein activated by adenylyl cyclase; MAPK, mitogen-activated protein kinase; CREB,
AMP response element binding protein; p70S6K, p70S6 kinase; PI3K, phospho-
nositide 3-kinase; NF-B, nuclear factor-B; AP1, activator protein 1; STAT3, signal
ransducer and activator of transcription-3.           
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f  Hong Kong, Shatin, NT, Hong Kong, China. Tel.: +852 2609 6886;
ax: +852 2607 5139.
E-mail address: xiaoheilzj@126.com (Z. Li).
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© 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY license.(5) induction of angiogenesis, (6) activation of invasion and
metastasis, (7) deregulation of cellular energetics and (8) insen-
sitivity of immune destruction [1,2]. A variety of stimulations and
signals associated with tumour development are involved in one
step or multiple steps of the eight hallmarks or other unapprehend
processes to some extent. Tumorigenesis is a multistep and compli-
cated process which is controlled by a cross-connected biological
network. Tumour mass is not an independent entity only consist-
ing of proliferative cancer cells. It recruits multiple distinct types of
normal cells to form tumour-associated stroma, and further devel-
ops vasculature, lymphatic and nervous systems to build up its
own microenvironment [1,3]. Neoangiogenesis, lymphangiogene-
sis and neoneurogenesis are being considered to occur in concert
and synergistically orchestrate the development, progression and
responsiveness to the prevention and therapy of tumours [4,5].
Experimental and clinical evidences also show that some cancers
are innervated by nerve ﬁbres and form neuro-neoplastic synapses
which directly secret neurotransmitters to act on the cancer cells
[6,7]. Cancer cells not only express receptors of neurotransmitters
but also are able to synthesize several different neurotransmitters
[3,8]. Some of them could act locally in an autocrine and paracrine
manners or systemically circulate and be back to tumour cells to
conduct relevant regulation on these cells.
-Adrenergic system consists of catecholamines and their
respective receptors including - and -adrenergic receptors
© 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY license.which are widely expressed in most of the mammalian tissues.
Adrenaline and noradrenaline are classic neurotransmitters
mediating ﬁght-to-ﬂight stress responses via sympatho-
adrenomedullary system [9,10]. Noradrenaline is released
534 J. Tang et al. / Seminars in Cancer Biology 23P (2013) 533– 542
Fig. 1. Stress hormones in cancer development and progression. A variety of physical and lifestyle stress induce the elevation of stress hormones in the body which are mainly
released  from adrenal gland and sympathetic nervous system. Adrenal gland receives the regulation of adrenocorticotrophic hormone (ACTH) resulting from the activation
of  pituitary in the hypothalamic–pituitary–adrenal axis after stress stimulation. On the other hand, nicotine from cigarette smoking is able to stimulate tumour cells to
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eurotransmitters. Finally, stress hormones originated from different systems contr
eurogenesis, tumour growth and metastasis.
rimarily from the sympathetic nerves and adrenaline is secreted
ainly by the adrenal medulla. Their release and secretion are
riggered by stimulation of the nicotinic/acetylcholine system
n the central and peripheral sympathetic nervous systems and
n the adrenal medulla (Fig. 1). Recent studies further disclose
hat some cancer cells contain all the enzymes for the adrenaline
ynthesis and are capable to secrete adrenaline after stimulation,
or example by nicotine [11–13]. Adrenaline and noradrenalineumour cells might be innervated by nerve ﬁbres which could also release relevant
to tumour development and progression such as angiogenesis, lymphangiogenesis,
could bind to -adrenoceptors with different afﬁnities. Adrenaline
preferentially binds to 2-adrenoceptors whereas noradrenaline
shows higher afﬁnity to 1-receptors [14]. Recently, a growing
number of studies suggest that biobehavioural factors especially
various stress-related persistent stimulations might accelerate
cancer progression, which is mainly contributed by -adrenergic
system activation (Fig. 1) [15–17]. In this review, we will focus
on the inﬂuences of -adrenergic system on several crucial steps
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n cancer development and progression, and further discuss the
otential applications of -blockers in cancer treatment.
. -Adrenergic system modulates biological behaviour of
umours
The roles of -adrenergic system in cancer development and
rogression almost involve in every hallmarks of cancer devel-
pment described above. The inﬂuences of -adrenergic system
n energy metabolism and immune system have been shown to
egulate cancer metastasis [8,18–20]. But here we focus on the
iscussion on the common tumorigenic pathways during tumour
rogression. They have been extensively investigated between the
elationship of -adrenergic system and tumorigenic processes
uch as cellular proliferation and apoptosis and also the vascu-
ar events including angiogenesis and vasculature normalization
hich are important in cancer cell invasion and metastasis dur-
ng cancer development. Table 1 summarizes the common cancer
ypes, their functional roles, and possible signal molecules and
eceptor subtypes which are associated with the activation of -
drenergic system.
.1. Promotion of cell proliferation and evasion of apoptosisIt has been demonstrated that high level of stress stimulation
ould contribute to disease progression, including various kinds of
ancer. The stress derived from social isolation was found to elevate
he tumour noradrenaline level in ovarian cancer patients, and its
able 1
he common cancers reported to be affected by -adrenergic system.
Tumour types -Adrenoceptor subtype Effects on tumours 
Pancreas 1 and 2 Proliferation
Migration
Invasion
Breast 1 and 2 Anti-apoptosis(2)a
Migration
Adhesion
Metastasis
Ovary 2 Anti-apoptosis
Tumour growth
Angiogenesis
Migration
invasion
Colorectum 1 and 2 Cell proliferation
Tumour growth
Migration(2)a
Metastasis
Oesophagus 1 and 2 Cell proliferation 
Stomach 1 and 2 Cell proliferation 
Lung 1 and 2 Cell proliferation
Tumour growth
Prostate 2 Anti-apoptosis
Migration
Metastasis
Nasopharynx 1 and 2 Angiogenesis
Invasion
Melanoma 1 and 2 Angiogenesis
Invasion
Leukaemia 1 and 2 Tumour growth
Metastasis
Hemangioma 1 and 2, predominantly
2
Cell proliferation 
Hemangioendotheliom 1 and 2 Cell proliferation 
Angiosarcoma 1 and 2 Cell proliferation 
a Relevant functions were mainly mediated by 2-adrenoceptors reported according 
yclooxygenase-2 inhibitor; GABA, an inhibitory neurotransmitter -aminobutyric acid.iology 23P (2013) 533– 542 535
level was  correlated with tumour grades and stages [21]. A grow-
ing body of investigations have suggested that stress hormones
adrenaline and/or noradrenaline exhibit a tumour-promoting func-
tion in a variety of tumour types including but not limited to the
cancers of pancreas [22], breast [23], ovary [24,25], colorectum [26],
oesophagus [27], lung [28,29], prostate [30], nasopharynx [31],
melanoma [32], leukaemia [33,34], even hemangioendotheliom
and angiosarcoma [35]. Among these tumours, pancreatic, breast,
ovarian and colorectal cancers have been extensively investigated
about the effects of -adrenoceptor system in preclinical and clin-
ical settings. The study from Thaker and colleagues [24] revealed
that chronic stress could elevate the tumour noradrenaline level
in an orthotopic ovarian cancer in a mouse model and obviously
increased tumour burden and aggressiveness of tumour growth.
Propranolol, a non-selective -adrenoceptor antagonist, com-
pletely abolished the effects of chronic stress on tumour growth. In
contrast terbutaline, a 2-adrenoceptor agonist produced a similar
increase in tumour weight just like under chronic stress. Further
study through various experiments by inhibition/elimination of
-adrenoceptors demonstrated that it was the 2-adrenoceptor
on the ovarian tumour cells mainly mediating the signal trans-
duction and tumour development initiated by chronic stress. But
Sood et al. [36] uncovered a different tumorigenic mechanism in
the regulation of adrenergic system in ovarian tumour growth.
In this regard it was thought to inhibit anoikis, a form of pro-
grammed cell death (apoptosis) when cells are separated from
ECM and proximal cells. They showed that human ovarian cancer
cells displayed a lower level of anoikis when cells were stimulated
Blockers References
Propranolol
ICI118, 551, Metoprolol,
Celecoxib,
GABA
[58,60,113]
Propranolol [30,59,62,63]
Propranolol [24,25,36,57,61,99,100]
Atenolol,
ICI118,551
[26,38,56,77,114]
Atenolol,
ICI118,551
Propranolol
ICI118,551,
Atenolol,
[78,115]
Propranolol
GABA
[29,70,116]
ICI118,551
Propranolol
[30,37,59,64]
Propranolol [31]
Propranolol [31,32]
Propranolol [33]
ICI118,551,
Metoprolol
[117]
Propranolol [35]
Propranolol [35]
to reference papers. Metoprolol, a 1-selective antagonist; Celecoxib, a selective
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y either adrenaline or noradrenaline. In a mouse model in which
nimals were exposed to chronic stress, hormones related to
tress inhibited anoikis in cancer cells. This action could promote
umour growth through activation of focal adhesion kinase (FAK).
nother study in prostate and breast cancer cells also demon-
trated that adrenaline stimulation reduced the sensitivity of
ancer cells to apoptosis through 2-adrenoceptors/protein kinase
 (PKA)/inactivation of proapoptotic protein BCL2-associated death
romoter (BAD)[30]. A recent investigation in preclinical model
urther conﬁrmed that stress hormone like adrenaline promoted
rostate carcinogenesis through inhibition of apoptosis and tumour
nvolution mediated by an adrenaline/2-adrenoceptor/PKA/BAD
ntiapoptotic signalling pathway [37]. Our laboratory also observed
hat both adrenaline and noradrenaline could induce proliferation
f colorectal cancer cells through -adrenoceptors, preferentially
he 2 receptors [26,38]. In contrast, there are reports showing
 different action of -adrenoceptor activation on breast cancer
ells. In these studies -adrenoceptor agonists could decrease cell
roliferation in vitro and reduce tumour growth in vivo [39,40].
he reasons of this paradoxical nature of observations remain
nknown. It might involve possible antagonistic action of some
-adrenoceptor agonists, different molecular signals and single
ucleotide polymorphisms of -adrenoceptor in the same cancer
ells [39,41].
.2. Induction of angiogenesis
It is well-known that angiogenesis is essential for tumour
rowth and metastasis. Physiologically, the ﬁne equilibrium
etween pro- and anti-angiogenic factors governs the complex pro-
ess and angiogenic switch is off in normal tissues [42]. Cancer is
he pathological condition that can tilt the balance towards more
timulatory angiogenic factors to drive the uncontrolled angio-
enesis with distinct immature vascular structures from normal
lood vessels [42,43]. Common pro-angiogenic factors include vas-
ular endothelial growth factors (VEGFs), placenta-derived growth
actor (PlGF), platelet-derived growth factor (PDGF), transfor-
ing growth factor (TGF-), hypoxia-inducible factor-1 (HIF-1˛),
ngiopoietin-2, insulin-like growth factor, and several chemokines
44]. Among these factors, VEGF is the most studied and best
alidated as pro-angiogenic molecule in tumour angiogenesis.
olid evidence derived from several cancer models has proven
hat adrenaline and noradrenline could upregulate the expres-
ion of VEGF and induce tumour angiogenesis and aggressive
rowth [24,25,31,45,46]. Besides VEGF, several reports from differ-
nt groups [24,31,32,46,47] also identiﬁed that other angiogenic
actors such as interleukin 6 (IL-6), IL-8, matrix metalloproteinase
MMP)-2 and MMP-9 could be elevated by the stimulation of
drenaline and noradrenaline in a diversity of cancer cells via
-adrenergic receptor signalling. These ﬁndings implicate that
n ampliﬁcation cascade might exist among these factors that
ynergistically strengthen angiogenesis and aggressive develop-
ent of tumours. But administration of -adrenoceptor antagonist,
ropranolol could completely abrogate the secretion of these
actors and their mediated functions, implying that -blockers
ave potential therapeutic value for the management of rel-
vant cancers. Furthermore, Lutgendorf et al. [48] illuminated
hat noradrenaline not only induced the increase of MMP-9 and
EGF in ovarian cancer cells but also stimulated the secretion
f MMP-9 in macrophages isolated from ovarian cancer speci-
ens. It has been shown that tumour associated macrophages
TAM) and MMP9 released by TAM play an essential role in angio-
enesis through presenting VEGF access to relevant receptors on
ndothelial cells and degrading extracellular matrix to release other
ro-angiogenic factors [49,50]. Additionally, a recent study by Park
t al. [51] unravelled that noradrenaline induced VEGF expressioniology 23P (2013) 533– 542
in several cancer cell lines from prostate, breast and liver via a
HIF-1-dependent manner. Further investigation disclosed that a
-blocker propranolol could completely abolish VEGF production
and reduce HIF-1 expression initiated by noradrenaline in cancer
cells [51].
2.3. Enhancement of invasion and metastasis
Tumour metastasis as a main cause of cancer-related death is
a multistep in cellular/biological process involving the invasion-
metastasis cascade. A sequence of molecular events are used to
delineate the process including cancer cell local invasion, intrava-
sation, transportation, inoculation, extravasation, micrometastasis
formation and colonization (metastatic macroscopic tumour for-
mation) [1,52,53]. Activation of -adrenergic system seems to
involve in each step of the cancer invasion-metastasis cascade.
Preclinical investigations have indicated that administration of -
blockers in perioperative and postoperative periods can improve
immune status and inhibit cancer metastasis in several cancer
models [54–56]. Substantial evidence has demonstrated that stress
hormones adrenaline and noradrenaline can induce the release of
MMP-2, MMP-7 and MMP-9 in a couple of cancer cell lines and
models which are highly associated with metastasis through degra-
dation of extracellular matrix to facilitate cancer cell invasion and
migration [24,31,57]. But -blockers, especially 2-antagonists,
can suppress the secretion of MMPs  and reverse the effects related
to MMPs  such as invasion and migration [58–61]. Strell and
colleagues [62] further found that noradrenaline promoted the
adhesion of breast cancer cell MDA-MB-231 to human pulmonary
microvascular endothelial cells (HMVEC) through the release of
growth-regulated oncogene alpha (GRO) and 1-integrin path-
way. The process analogizes the extravasation of cancer cells into
secondary metastatic loci. Accordingly, -blockers could abrogate
the effects initiated by noradrenaline. Sloan et al. [63] illustrated
in an orthotopic mouse model of breast cancer in which stress
stimulation or pharmacological activation of -adrenergic sys-
tem by isoproterenol induced a 30-fold increase in metastasis to
distant organs, which might be mediated by the inﬁltration of
macrophages into primary tumour parenchyma. Stress-induced
macrophages can produce the expression of many pro-metastatic
genes and exhibit the intendancy towards M2-like differentiation
related to aggressive tumour development. Consistently, -blocker
propranolol and macrophage suppressor GW2580 can signiﬁcantly
repress the stress-induced metastasis. A similar result has also been
reported in a human prostate cancer cell mouse model [64]. As a
result of these investigations, it is suggested that stimulation by
stress hormones might switch on metastasis signals during the car-
cinogenesis of different types of cancer and -blockers hold great
promise to inhibit the initiation and development of metastasis in
solid tumours.
2.4. The transactivation of ˇ-adrenoceptors by nicotine and its
derivatives
It is known that the synthesis and release of catecholamines
are regulated by nicotinic acetylcholine receptors (nAChR) dis-
tributed in adrenal medulla and sympathetic nervous endings
[3,65]. Cigarette smoking is thought to be a risk factor associ-
ated with different types of cancer. Nicotine as a well-documented
component in tobacco is believed to be responsible for various
cardiovascular diseases and also to promote the relevant tumour
progression through binding to nAChR in the nervous system or
non-neuronal mammalian cells. A large number of publications
have documented that nicotine is capable of inducing proliferation
and invasion of various cancer cells in vitro and tumour growth
and metastasis in vivo [65–68]. Another important component
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erived from nicotine is nitrosamine, 4-(methylnitrosamino)-1-
3-pyridyl)-1-butanone (NNK) which has been proved to exhibit
 stronger potential as a carcinogen in induction and promotion
f various tumour development through the binding with higher
fﬁnity to AChR than the natural ligand acetylcholine [13,28]. Due
o the close connection among nicotine/NNK, nAChR and cate-
holamines, there should be no surprise that nicotine or NNK can
timulate the secretion of adrenaline and noradrenaline in cancer
ells, which can further enhance the nicotine-driven tumour devel-
pment through aforementioned functions of stress hormones in
ancer cells [69–72]. Our laboratory has been focusing on study-
ng the interaction between cigarette smoking and gastrointestinal
ract cancers for a number of years. It was found that nicotine,
NK or cigarette extract could not only induce cell proliferation
n vitro in a variety of human cancer cells from the upper to the
ower gastrointestinal tract, but also promote tumour growth and
ngiogenesis in vivo through nAChR activation. Nicotine nAChR
ntagonist could block the effect of nicotine and the down-stream
ignal transduction [73–76]. Subsequently, we also found that the
timulatory action of NNK on colon cancer cell proliferation could
e inhibited by -blockers [38], and nicotine could induce the syn-
hesis and release of adrenaline in colon cancer cells and -blockers
ould reverse nicotine-induced cell proliferation [11]. Similar ﬁnd-
ng was reported in mice [12]. Interestingly it was  found that
igarette smoking together with stress synergistically enhanced
olon tumour growth in the same type of animals [77]. Both stress
ormone and cigarette smoke active components produced similar
timulatory action on oesophageal and gastric cancer cells via the
-adrenoceptors [27,78,79].
Recently, several reports from the group of Al-Wade and col-
eagues [13,28,80] unravelled that nicotine or NNK could reduce
he production of inhibitory neurotransmitter -aminobutyric
cid (GABA) when they stimulated the synthesis and release of
drenaline and noradrenaline in the cancers of pancreas and lung.
n fact GABA administration could reduce the responses from nico-
ine stimulation and also inhibit the development of tumours in
ice [81]. Likewise, GABA treatment directly reverses the effects of
tress on non-small cell lung cancer [29]. All these ﬁndings suggest
hat besides -blockers, GABA is also a promising agent to be devel-
ped to intervene cancers causally related to stress and cigarette
moking.
. -Adrenoceptors and -blockers, possible roles in
umour blood vessel normalization
As previously mentioned, stress hormones could induce angio-
enesis in tumours through the release of pro-angiogenic factors.
t has been well-documented and accepted that the structure of
umour blood vessels is distinguished from those from normal tis-
ues [82,83]. Tumour vasculature is often dilated, tortuous, leaky
nd uneven in diameter. These blood vessels also exhibit an het-
rogeneous distribution in a tumour mass, in which hypervascular
nd hypovascular areas could be visualized [84]. Additionally,
he perivascular cells (PVCs) consisting of pericytes and vascular
mooth muscle cells are often absent or detached from endothelial
ells (ECs). The PVCs-ECs dissociation is thought to be promoted
y numerous pro-angiogenic factors released in the development
f tumours [84]. These immature angiogenesis in tumour tissues
nally leads to a hostile tumour microenvironment characterized
y hypoxia, patchy hypoperfusion, low pH and a high interstitial
uid pressure [85,86]. The abnormality of tumour blood vessels
an aggravate the vessel disorganization by hypoxia stimulation,
mpede the transport and distribution of anti-cancer drugs and oxy-
en, inhibit the function of immune system, and produce a resistant
apacity of cancer cells against various therapies such as radiation,
hemotherapy and immune modulation [85,87]. In the past decade,iology 23P (2013) 533– 542 537
various strategies had been devised to normalize tumour blood
vessels. These have been pursued to improve or remodel vessel
structure and function. Both preclinical and clinical experimen-
tal data have shown that normalized tumour vessels can improve
the efﬁcacy of immunotherapy, increase drug delivery and absorp-
tion of anti-cancer drugs, and decrease and delay intravastion and
metastasis [87,88]. Both genetic alteration and pharmacological
intervention can induce the normalization of tumour blood ves-
sels. For example, overexpression of histidine-rich glycoprotein
(HRG) in mice [89] resulted in normalization of tumour vessels with
increased PVC coverage and blood perfusion, and reduced hypoxia.
Meanwhile, HRG-induced normalization decreased tumour growth
and metastasis and enhanced the efﬁcacy of chemotherapy; even
regulate the polarization of tumour-associated macrophage pheno-
type. Another typical example is the anti-VEGF antibody therapy.
Anti-VEGF antibody bevacizumab when combined with systemic
chemotherapy signiﬁcantly improved progression-free survival
and overall survival when compared with chemotherapy alone
[87]. Mechanistic study reveals that suitable dose of anti-VEGF
antibody can remodel tumour blood vessels, restore oxygenation,
reduce hypoxia, leading to enhanced efﬁcacy of chemotherapies
[88]. Ample evidence also suggested that some anti-angiogenesis
agents could pharmacologically induce vascular normalization in a
transient manner and in a special time window [87].
Thaker et al. [24] reported that chronic stress could induce
tumour growth and promote angiogenesis in a mouse model bear-
ing ovarian cancer. Further analysis unveiled that stress obviously
increased mean vessel density but -blocker propranolol reversed
the effect. Histological ﬁnding showed that tumours in stress ani-
mals consisted of more tortuous vasculature than the control
accompanied with a 24% reduction of pericyte coverage, which is a
typical characteristic of immature and abnormal tumour vessels.
But in this study, the author did not mention whether admin-
istration of -blocker propranolol could normalize the tumour
vasculature. A recent report from the same group [90] demon-
strated that dopamine (DA), an inhibitory neurotransmitter which
has been proven to be able to antagonize the effect of stress
hormones on cancer development, could abrogate the tumour
vasculature and ovarian cancer growth driven by chronic stress.
Further studies found that administration of DA resulted in a
decrease of microvessel density through dopamine receptor 2
(DR2), and stabilization of tumour blood vessels characterized by
increased pericyte recruitment to EC through DR1. Moreover, DA-
induced normalization enhanced the absorption of cisplatin in
mice. But -blocker as an antagonists on stress hormones were not
assessed in this study. Another similar investigation on prostate and
colon cancers [91] also suggested that exogenous administration of
DA could normalize the structure of tumour blood vessels in both
cancer models through acting on the DR2 expressed on pericytes
and endothelial cells. Consequently, normalization of tumour vas-
culature improved the concentration and efﬁcacy of 5-ﬂuorouracil.
It is well-established that DA or GABA as an inhibitory neurotrans-
mitter antagonizes the function of stress hormones. These studies
would be prone us to believe that -blockers like other inhibitory
neurotransmitters such as GABA and DA discussed above could also
normalize blood vessels in cancers. Further investigation is needed
to clarify the roles of -adrenergic system in the normalization of
tumour blood vessels and its implications in the treatment of solid
tumours in the near future.
4. -Adrenoceptor signal transduction related to cancer
development and progressionPhysiologically, activation of -adrenoceptor system is involved
in a couple of signal transduction pathways dependent on ligand,
adrenoceptor conformation, tissue environments and functions
538 J. Tang et al. / Seminars in Cancer Biology 23P (2013) 533– 542
Fig. 2. Possible signal pathways of -adrenergic system in cancer. -Adrenoceptors stimulated by stress hormones activate AC via Gs protein released from G proteins,
resulting in the increase of second messenger cAMP. The cAMP activates PKA protein which can mediate multiple signal pathways via phosphorylation of various downstream
signal  proteins. PKA-CREB pathway is a well-deﬁned pathway which results in synthesis of several angiogenic factors through the transcription regulation mediated by
phosphorylated CREB binding to CRE (F). But direct G protein/Src (related to actin)/FAK phosphorylation pathway mediates the anoikis inhibition and anti-apoptosis (A).
The  protection of cancer cells from apoptosis could also be regulated by the phosphorylation of cAMP/PKA-dependent BAD (B). The stress hormones induce the activation of
AMP/PKA/PI3K/AKT/mTOR/p70S6K/HIF1,  leading to VEGF synthesis via HIF1-mediated transcription regulation (C). PKA-dependent Src phosphorylation might promote
the  metastasis via various downstream effectors (D). SATA3 activation induced by stress stimulation is able to regulate the synthesis of MMPs  which are highly associated
with  tumour metastasis (E). FosB stimulated by stress/cAMP signal might constitute a complex with AP-1 to increase IL-8, which could drive tumour growth and metastasis
(G).  MAPK pathway activated by stress factors can stimulate various transcription factors such as CREB, AP-1 and NF-B to induce the secretion of VEGFs and MMPs (H). In
addition, macrophages stimulated by stress hormones can produce a list of angiogenic and prometastatic factors which inﬂuence tumour progression (I). Collectively, various
signal  pathways induced by stress hormones ﬁnally accelerate tumour growth, angiogenesis, as well as metastasis dissemination via a large number of tumour-related factors.
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92]. Due to widespread distribution in the body and important
oles in cardiovascular and central nervous systems, related sig-
al pathways have been systematically investigated and reported,
hich makes -adrenoceptors become valuable drug targets to
esign agonists and antagonists to regulate alternative signal
athways with intervention against clinical diseases [93–96].
lassically, -adrenoceptors as G protein-coupled receptors in
esponse to stress hormones activate the adenylyl cyclase (AC)
hrough Gs and elevate the second messenger cyclic AMP  (cAMP)
hich activates PKA (Fig. 2). Subsequent signal pathways are
ormally divided into PKA-dependent and independent signal
ransduction. PKA is able to phosphorylate numerous proteins
o realize relevant function regulations. For PKA-independent
athway, a representative instance is the exchange protein acti-
ated by adenylyl cyclase (EPAC) mediated signal transduction
n which AC after adrenoceptor activation directly activates
PAC resulting in stimulation of mitogen-activated protein kinase
MAPK) signal pathways [96,97]. However, substantial evidence
isclosed that -adrenoceptors could also initiate and activate
ome signal pathways independent of the G proteins [92]. A
ell-characterized example is -arrestin-mediated activation of
APK pathways via triggered 2-adrenoceptors in which stimu-
ation of 2-adrenoceptors directly recruits relevant signal protein
uch as c-Src and the receptor via -arrestin but not the G pro-
eins [92,95,98]. Here we will describe several -adrenoceptor
ignal pathways related to cancer development and progression.
ig. 2 presents the common -adrenoceptor signal pathways in
ancer development. As we discussed above, stimulation of -
drenoceptors by stress hormones promotes the release of several
ro-angiogenic factors, such as VEGF, MT1-MMP, MMP-2, MMP-
, IL-6, leading to tumour growth and angiogenesis. The process
s mostly mediated by AC-cAMP-PKA pathway. PKA enables tran-
cription factor cAMP response element binding protein (CREB)
o be phosphorylated, which promotes the binding of CREB to
he cAMP response element (CRB) and induces the transcription
f genes encoding these factors [14,24,28,59]. Furthermore, Park
nd colleagues [51] unveiled another mechanism of VEGF-induced
xpression dependent on HIF1 protein after adrenoceptor acti-
ation by noradrenaline, which is involved in the process of
he cAMP/PKA/phosphoinositide 3-kinase (PI3K)/Akt/mTOR/p70S6
inase (p70S6K)/HIF1/VEGF signal transduction. Additionally,
KA-independent pathways were reported to involve the activa-
ion of transcription factors nuclear factor B (NFB) and activator
rotein 1(AP1) besides CREB, all of which could regulate the tran-
cription of VEGF, MMPs  and interleukins. Zhang et al. [60] found
hat -adrenoceptor antagonists ICI118,551 and propranolol could
timulate the c-Src-mediated Ras/Raf/MAPK pathway to regulate
he activity of transcription factors CREB, AP1 and NF-B in pan-
reatic cancer cells.
In stress hormone-mediated protection of cancer cell from apo-
tosis, Sood and colleagues [36] elucidated that stimulation of
2-adrenoceptors could lower the level of anoiks through direct
ctivation of actin- related Src and subsequent phosphorylation
f focal adhesion kinase (FAK)Y397 in ovarian cancer cells. High
evel of pFAKY397 was found in ovarian cancer patients with
ehavioural stress states related to adrenergic activity. But Sastry
t al. [30] reported that a major anti-apoptotic mechanism is the
KA-dependent BAD phosphorylation at site S112 after activation
f 2-adrenoceptors by adrenaline in prostate and breast cancer
ells. Thus, cancer types might be one of important determinants
n selection of signal pathways in the context of activation of -
drenergic system. On the other hand, the metastasis initiated by
-adrenergic system is driven by a distinct set of signal pathways
n different cancer cells. A recent study by Armaiz-Pena group [99]
lluminated that -adrenoceptor activation might switch on the
etastasis process in ovarian cancer via Src phosphorylation at siteiology 23P (2013) 533– 542 539
Y419 following after at site S17 phosphorylation which is required
to expose site Y419. But the noradrenaline-induced Src activation is
cAMP/PKA dependent. Additionally, signal transducer and activa-
tor of transcription-3 (STAT3), FosB-induced IL-8 signal pathways
possibly also drove the growth, invasion and metastasis in ovarian
cancer in the cAMP and/or PKA dependent manners [61,100]. Sloan
et al. [63] demonstrated that macrophage inﬁltration into primary
breast cancer parenchyma might trigger a metastatic switch via
activation of -adrenergic system since invasive macrophage acti-
vated by stress hormones produced various pro-metastatic factors,
resulting in secondary metastasis in distant tissues.
Signal network implicates that there are complicated connec-
tions and cross talks among signal molecules. Although activation
of -adrenergic system could trigger multiple signal pathways
in different cancer cells, we cannot rule out the synergic effects
among these signal pathways. It is evident that direct blocking
the -adrenoceptors has a great potential to be able to intervene
cancer related signal pathways, resulting in alleviation of cancer
progression.
5. -Blockers, a new opportunity for conventional drugs
We have discussed that stress hormones are highly associated
with tumour growth, invasion, and metastasis via activation of
-adrenoceptors in preclinical and clinical settings. Meanwhile,
-blockers could abrogate partly or completely the pathological
impact of stress hormones on tumour progression in preclinical
settings. -Blockers are clinically well characterized and have been
safely administered as therapeutics for cardiovascular diseases,
especially hypertension for decades. As reported in this review, -
blockers should have additional potential to be exploited clinically
to alleviate the deleterious progression of cancers inﬂuenced by
-adrenergic system. If that is the case, application of -blockers
in cancer therapy could be novel and safe. It is also cost-effective
as adjuvant chemotherapeutic agents for cancer treatment. Inter-
estingly, a couple of retrospective studies strongly supported the
beneﬁcial actions of -blockers in relevant cancer treatment. First,
an earlier retrospective analysis carried out by Perron et al. in
a large case-control study of prostate patients showed that of
the different classes of antihypertensives, only -blockers were
correlated to a reduction in prostate cancer risk [101]. Another
cohort study involved 839 patients with cardiovascular disease
followed up for 10 years suggested that -blocker users had a sig-
niﬁcant decrease in cancer incidence compared with those never
used [102]. But another two studies in relatively larger popula-
tion did not support that -blockers had a signiﬁcant association
with lower risk of prostate cancer [103] or increase cancer risk
[104]. These conﬂicting results would make -blockers more com-
plex in the role of tumour prevention and occurrence. Recently,
several new investigations disclosed that -blockers might have
the ability to repress cancer progression in established cancers,
especially breast cancer and melanoma. A more than 10-year ret-
rospective study from Powe et al. [105] reported that breast cancer
patients receiving -blockers for hypertension exhibited an obvi-
ous reduction in metastasis development, tumour recurrence and
cancer-speciﬁc mortality. Another two  population-based studies
by Barron et al. and Melhem-Bertrandt et al. achieved similar and
consistent conclusions in breast cancer patients. Barron et al. [106]
reported that 1/2 non-selective blocker propranolol signiﬁcantly
reduced the primary tumour development, nodal/metastatic occur-
rence and breast cancer-speciﬁc mortality but not for 1-blocker
atenolol. The ﬁnding also suggests that 2-adrenergic pathway is
a predominant mediator for the therapeutic action of propranolol.
Melhem-Bertrandt et al. [107] found that -blockers signiﬁcantly
improved the relapse-free survival in all patients with breast
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ancer and in patients with triple-negative breast cancer (oestrogen
eceptor-negative/progesterone receptor-negative/human epider-
al  growth factor-negative). But in this study, the conclusion was
ased on the patients using 1-blocker, which is in contrast with
he conclusion of Barron et al. who found no signiﬁcant bene-
ts for 1-blockers in breast cancer patients. In fact, selective
1-blockers often indicate off-target function through the afﬁn-
ty to other -adrenoceptors [107]. Thus, more broad -blockers
r more exact adrenoceptor identiﬁcation are needed in future
nvestigations. For melanoma, two reports from different groups
ndicated that -blocker intake might reduce the risk of progres-
ion in patients with thick melanoma [108] and increase survival
ime of patients with melanoma [109]. But a contradicting ﬁnd-
ng by Shah et al. [110] pointed out that -blocker treatment had
o evident beneﬁcial effect on overall survival of patients with
ommon human tumours such as cancers in the lung, breast and
olon, and even produced poorer survival in patients with prostate
nd pancreatic cancers. Although controversial conclusions are
resent for the application of -blockers in cancer treatment, it
s noticeable that all of the aforementioned investigations are
opulation-based retrospective studies which limited the interpre-
ation of the results to some extent. It is time to design clinical
rials to test -blockers in adjuvant treatment of relevant can-
ers, especially breast cancer. Some important issues need to be
onsidered for future studies including but not limited to blocker
electivity, dose titration and local concentration in tumour mass,
-adrenoceptor expression, tumour types and stages, and inter-
ction of -blockers and tumour microenvironment [111,112].
ased on preclinical translational data and retrospective analy-
is, we predict that -blockers hold considerable promise to treat
atients with some cancers in the future as a class of well-deﬁned
onventional drug used for cardiovascular diseases in the past
ecades.
. Summary and perspectives
Numerous evidences from preclinical and epidemiological stud-
es have implicated that stress hormones or behavioural changes
re highly associated with tumour formation and progression.
atients diagnosed with cancer often endure different degree of
tress complicated with high of stress hormones. Likewise nico-
ine/NNK from cigarette smoke can also stimulate the secretion of
tress hormones in cancer patients. All these could stimulate the
drenergic system. It is known that over activation of -adrenergic
ystem could accelerate cancer development through multiple-
tep process. An increasing body of information from preclinical
nvestigations and clinical retrospective analysis have shown that
-blockers as a class of drug broadly used for hypertension reg-
lation have great potential to be used to treat cancer patients
mpacted by psychological stress. However there is no exact con-
lusion that can be drawn so far from retrospective clinical studies.
t is time to launch a well-designed and meticulous clinical trial to
fﬁrm the exact role and clinical application of -blockers in the
reatment of cancer patients. On the other hand, it is worthwhile to
xplore the mechanistic action of -blockers in the normalization
f tumour blood vessels. Indeed it is an emerging and promising
herapeutic strategy that vessel remodelling agents in combina-
ion with chemotherapeutic drugs are being exploited to treat
atients with solid tumours. Meanwhile, inhibitory neurotransmit-
ers such as GABA and dopamine should also play a signiﬁcant role
n the future in cancer therapy since they can antagonize the car-
inogenic action of -adrenergic system which could be activated
uring the progression of cancer development. Collectively, -
drenoceptors are valuable drug targets to control the deleterious
ffects of -adrenergic system in tumour development together
ith psychological stress in cancer patients.iology 23P (2013) 533– 542
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